Allergan Confirms Generic Tyvaso® Patent Challenge

Your place for beaking medical news and career advice from top medical recruiters

DUBLIN, July 30, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Treprostinil Inhalation Solution, 0.6 mg/mL, 2.9 mL ampules.  Allergan’s ANDA product is a generic version of United Therapeutics Corporation’s Tyvaso®, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. read more

MiMedx Announces Record Results for Second Quarter of 2015

Company Records Revenue of $45.7 million and Net Income of $5.4 million

MARIETTA, Ga., July 30, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the second quarter of 2015. read more

Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results

Company Points to Progress on Strategic Priorities as it Provides Fiscal 2016 Outlook

– 33 percent increase in non-GAAP1 operating earnings to $611 million for the fourth quarter

– 16 percent growth to record $2.5 billion in non-GAAP operating earnings for fiscal 2015

– 20 percent increase in non-GAAP diluted earnings per share from continuing operations to $1.00 for the fourth quarter

– 14 percent increase in non-GAAP diluted earnings per share from continuing operations to $4.38 for fiscal 2015

– Fiscal 2016 outlook for non-GAAP diluted earnings per share raised to $4.85 to $5.05, or 11 to 15 percent growth in FY2016

Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.

NEW YORK & TOKYO–(BUSINESS WIRE)–Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,“Kyowa Hakko Kirin”) and Bristol-Myers Squibb Company (NYSE:BMY, “Bristol-Myers Squibb”) today announced that the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1/2 combination study with mogamulizumab, an anti-CCR4 antibody and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor. The study, which will be conducted in the U.S., will focus on evaluating the safety, tolerability and anti-tumor activity of combining mogamulizumab and Opdivo as a potential treatment option for patients with advanced or metastatic solid tumors. Prior to this agreement, Kyowa Hakko Kirin, Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. (Tokyo: 4528) entered into a clinical trial collaboration agreement to study the combination of mogamulizumab and Opdivo in Japan. read more

Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients  

Fifty-two percent of patients achieved a partial response and 30 percent of patients had stable disease following treatment with PLX3397, an investigational CSF-1R inhibitor

– A rare tumor of the joint or tendon sheath, TGCT can lead to significant pain, stiffness, loss of mobility and joint destruction; currently no systemic therapy is approved for TGCT

– Pivotal phase 3 ENLIVEN study currently enrolling patients with locally advanced TGCT to further evaluate efficacy and safety of PLX3397 read more

CVS Health and IBM Tap Watson to Develop Care Management Solutions for Chronic Disease

WOONSOCKET, R.I. and ARMONK, N.Y., July 30, 2015 /PRNewswire/ — CVS Health (NYSE: CVS) and IBM (NYSE: IBM) today announced they will use predictive analytics and Watson cognitive computing to transform care management services for patients with chronic disease. read more

Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a global license and supply agreement with Sanofi to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor. Under the terms of the license, Ligand will be eligible to receive potential milestone payments, royalties on future net sales and revenue from Captisol material sales. Sanofi will be responsible for all costs related to the program. read more




Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.